Insight Molecular Diagnostics (IMDX)

• Market cap: $166M
• 1 day: -3.2%
• 5 days: -5.33%
• 1 month: -18.9%
• 3 months: 17.58%
• 6 months: -0.77%
• Year to date: -28.07%
• 1 year: 62.97%
• 5 years: -95.18%
• 10 years: -94.4%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Employees: 58